NH

Nancy Hong

Biotech Investor

San Diego Metropolitan Area

Investor
VC

Invests in

Stages:

Series A
Seed

  • Min Investment:

    $100,000.00

  • Max Investment:

    $10,000,000.00

  • Target Investment:

    $1,000,000.00

Skills

Biotechnology
Bioinformatics
Lifesciences
Drug Discovery
Molecular Biology
Genomics
Drug Development
Oncology
Clinical Development
Immunology
Pharmaceutical Industry
Technology Transfer
Biochemistry
Commercialization
Venture Capital
Cell Biology
Life Sciences
Biopharmaceuticals

Education

Investments

Bluejay Therapeutics

Series B

Total Funding: $220M

Biolinq

Series B

Total Funding: $110M

Scout Bio

Series B

Total Funding: $53M

SeQure Dx

Series A

Total Funding: $18M

Xilio Therapeutics

Series B

Total Funding: $330M

Work Experience

San Diego Symphony

2021

  • Board Member

    2021

Biolinq

2021 - 2023

  • Board Member

    2021 - 2023

Bluejay Therapeutics

2021 - 2023

  • Board Member

    2021 - 2023

SeQure Dx

2021 - 2023

  • Board Member

    2021 - 2023

Scout Bio

2019 - 2023

  • Board Member

    2019 - 2023

RiverVest Venture Partners

2016 - 2023

  • Managing Director

    2016 - 2023

    Dr. Hong focuses on biopharmaceutical and medical device opportunities and contributes to the formation, development and business strategies of RiverVest portfolio companies. Dr. Hong joined RiverVest in 2016 and is based in San Diego with Drs. Niall O’Donnell and Pascal Krotee.

Xilio Therapeutics, Inc.

2019 - 2021

  • Board Member and Observer

    2019 - 2021

    NASDAQ: XLO

BioMed Realty

2013 - 2016

  • Principal at BioMed Ventures

    2015 - 2016

  • Senior Associate at BioMed Ventures

    2013 - 2015

Independent

2010 - 2013

  • Biotech Consultant

    2010 - 2013

Genomics Institute of the Novartis Research Foundation

2009 - 2009

  • Scientist

    2009 - 2009

    Novel targets and projects